ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1482

LN Urinary Proteomics Reveals Common Biological Pathways Identified by Distinct Disease Measures

Paul Newcombe1, Madhu Ramaswamy2, Dominic Sinibaldi2, Catharina Lindholm3, Frederick Jones1, Ahmad Akhgar2, Philip Brohawn2, Raj Tummala2 and Wendy White2, 1BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 2BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 3BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

Meeting: ACR Convergence 2021

Keywords: Biomarkers, Lupus nephritis, Renal

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: SLE – Etiology & Pathogenesis Poster (1480–1506)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: LN is a severe consequence of SLE and there is a huge unmet need for discovery of urine protein biomarkers that provide non-invasive surrogates of disease activity and response to therapy. The purpose of this study was to measure protein biomarkers in urine samples from a diverse cohort of LN patients and to assess their correlations with patient demographics and clinical characteristics including the renal measures of estimated glomerular filtration rate (eGFR), SLEDAI-renal (SLEDAI-R) and National Institutes of Health Activity (NIH-AI) and chronicity (NIH-CI) indices

Methods: The demographics and characteristics of the cohort of 112 patients is described in Table 1. All patients fulfilled the 1997 ACR criteria for SLE and all had biopsy-proven LN. Urine samples from patients and 16 healthy donors (HD) were analyzed for 192 proteins by Luminex and 5 by SimoaTM. Protein concentrations were normalized to urinary creatinine levels. Log-concentrations of each protein was assessed for correlation with each clinical feature using linear regression adjusted for age, gender, ethnicity, disease duration, and treatment. eGFR was assessed using the cutoff of >60. The Benjamini-Hochberg procedure was used to calculate false discovery rates, with a cut-off of 0.1 used to determine significance. Statistical significance of intersections of protein lists was assessed via permutation. Pathway assessments were conducted using Ingenuity core analysis.

Results: Pre-filtering proteins for LN normalized mean concentrations to be greater than the HD mean + 1.5 SD yielded 97 distinct upregulated proteins. The largest numbers of protein-outcome associations were confounded by age (but not disease duration), gender, and MMF dose. After removing the influence of all confounders, numerous proteins showed statistically significant differential expression with respect to eGFR, SLEDAI-2K, SLEDAI-R, serum C3 and C4, NIH-AI, and NIH-CI. Conversely, no proteins were significantly correlated with LN class, race, or SDI (SLICC/ACR disease Index). The highest numbers of significant proteins were found for eGFR (55 proteins) followed by SLEDAI-R (36) and NIH-AI (20). There was a significant overlap of 11 proteins (Table 2) across these three lists (intersection p=4.1 × 10-5), indicating that these clinical renal measures share common biological processes. Pathway analysis of the 11 common proteins indicated enrichment for functions known to be associated with fatty acid/lipid metabolism, cardiovascular disease, cellular trafficking and immune cell infiltration

Conclusion: By analyzing LN urinary proteomics, we revealed that 3 clinical renal measures: eGFR, SLEDAI-R and NIH-AI are commonly associated with various proteins and pathways, most of which support the emerging importance of renal vascular pathology in LN.

Table 1

Table 2: 11 urinary proteins which reached statistical significance (false discovery rate < 0.1) for association with eGFR, SLEDAI-R and NIH-AI


Disclosures: P. Newcombe, AstraZeneca, 3; M. Ramaswamy, AstraZeneca, 3; D. Sinibaldi, AstraZeneca, 3; C. Lindholm, AstraZeneca, 3; F. Jones, AstraZeneca, 3; A. Akhgar, AstraZeneca, 3; P. Brohawn, AstraZeneca, 3, 11, Immunocore, 3; R. Tummala, AstraZeneca, 3; W. White, AstraZeneca, 3, 11.

To cite this abstract in AMA style:

Newcombe P, Ramaswamy M, Sinibaldi D, Lindholm C, Jones F, Akhgar A, Brohawn P, Tummala R, White W. LN Urinary Proteomics Reveals Common Biological Pathways Identified by Distinct Disease Measures [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/ln-urinary-proteomics-reveals-common-biological-pathways-identified-by-distinct-disease-measures/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ln-urinary-proteomics-reveals-common-biological-pathways-identified-by-distinct-disease-measures/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology